Overview
- Over the weekend, researchers from the Universities of Cambridge and Southampton reported a Phase I trial in 39 healthy volunteers that tested the first vaccine whose active ingredient was designed entirely by computer simulations.
- The trial found the candidate was well tolerated at all doses with no major safety concerns and it produced modest, cross‑reactive antibody signals rather than strong or definitive protection.
- The vaccine combines an AI‑designed 'super‑antigen' meant to include features common across sarbecoviruses with a DNA platform that is administered needle‑free using a high‑pressure microfluidic jet to deliver doses through the skin.
- Teams and the DIOSynVax spin‑out are preparing larger, more diverse Phase II studies to measure real‑world protection and durability of immunity before any claims of broad or 'future‑proof' coverage can be confirmed.
- Experts caution that AI design raises separate risks such as biased training data, erroneous outputs, liability and privacy questions, while the DNA and needle‑free delivery could still materially ease storage, transport and mass vaccination if efficacy is proven.